210-5212000, 210-5212054 www.keelpno.gr

1

2014-2015 (32) , (11)pdm09.

(32) (11)pdm09 , .

/ .

, 48 .

.

, 52/2014 . 6-8 1. . (32) (drifted) (32) 2014-2015. (11)2009pdm . 2014-2015 . drifted (32) . 2,3. , (32) , , (>99%) 2, .4-6 2014 , .7,

2014-2015

2015

210-5212000, 210-5212054 www.keelpno.gr

2

( 107) placebo 1 ( -16,8 ). , .7 2014 - ( 78 observationalstudies) (11)pdm09.8 - () 48 , . , . ( 1). : (32), (11)pdm09, , . 2014-2015 ( 1) : . , 48 . , ,

48

. . , / , . , , . ( 2). , 1 , . ( : 210-5212054 210-5222339).

1 .

210-5212000, 210-5212054 www.keelpno.gr

3

, . .

(: 788-3)

60

, :

o . o o . o o ( ) o o o

.

, () 40kgm/m2.

(.. Kawasaki, ..) Reye .

http://bit.ly/15DTmpC

210-5212000, 210-5212054 www.keelpno.gr

4

1. ( : A (H3N2), (H1N1)pdm09, B)

( ),

( )

,

,

( , )

( )

: ). 150mgx2x15

5

,

,

( , )

210-5212000, 210-5212054 www.keelpno.gr

5

2.

A.

() > 1 .

.

(13 17 )

: 75mgx 2 x 5 peros. , , (150mg x 2 x 15 ). . 12

12 , :

15 kg 30 mg x 2 x 5 per os

15-23 kg 45 mg x 2 x 5 per os

24-40 kg 60 mg x 2 x 5 per os

> 40 kg 75 mg x 2 x 5 per os

12 :

> 3 12 3 mg/kg x 2 x 5 per os

> 1 3 2.5 mg/kg x 2 x 5 per os

0 1 * 2 mg/kg x 2 x 5 per os

* < 1 .

30mg . , , . : http://www.eof.gr/assets/PL_Tamiflu.pdf

.

, . , 48 . :

, ,

http://www.eof.gr/assets/PL_Tamiflu.pdf

210-5212000, 210-5212054 www.keelpno.gr

6

,

, .

68-89%, . :

(13 17 ) : 75mgx 1 x7-10 peros.

12 , :

15 kg 30 mg x 1 x 7-10 per os

15-23 kg 45 mg x 1 x 7-10 per os

24-40 kg 60 mg x 1 x 7-10 per os

> 40 kg 75 mg x 1 x 7-10 per os

30mg . , 2 / 1 . .

B.

>7 , > 5 . . . !: .

.

10mgx 2 x 5 , x 2 x5 . - (210-5212054) . . !: , !

.

10mgx 1 x7-10 , x 1 x7-10 .

http://bit.ly/KGcWr0http://bit.ly/KGcWr0

210-5212000, 210-5212054 www.keelpno.gr

7

1: 9

1 . 2 . 3 , 2014-2015(: 788-3)

1

2

3

;

:

48

:

INH

,

;

:

INH/NEB/IV

:

NEB/ IVPO: INH: NEB: IV:

http://bit.ly/15DTmpC

210-5212000, 210-5212054 www.keelpno.gr

8

1. , , 3/2015 2. ECDC, Rapid Risk Assessment on circulation of drifted influenza A(H3N2) viruses in the EU/EEA, Available at:

http://www.ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List={4F55AD51-4AED-4D32-B960-AF70113DBB90}&ID=1234

3. CDC Health Advisory Regarding the Potential for Circulation of Drifted Influenza A (H3N2) Viruses, CDCHAN-00374, Available at http://emergency.cdc.gov/han/han00374.asp

4. CDC, Atlanta: Guidance on the Use of Influenza Antiviral Agents. Available at: http://www.cdc.gov/flu/professionals/antivirals/antiviral-use-influenza.htm#chemoprophylaxis

5. TA168 Amantadine, oseltamivir and zanamivir for the treatment of influenza: review of NICE technology appraisal guidance 58. February 2009 Available at: http://guidance.nice.org.uk/TA168

6. WHO guidelines for pharmacological management of pandemic influenza (H1N1)2009 and other influenza viruses. Feb 2010. Available at: http://www.who.int/csr/resources/publications/swineflu/h1n1_use_antivirals_20090820/en

7. Jefferson T, Jones MA, Doshi P, Del Mar CB, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No.: CD008965. DOI: 10.1002/14651858.CD008965.pub4.

8. Muthun SG, Venkatesan S, Myles PR, Leonardi-Bee J, et al. LancetRespir Med 2014;2: 395404 9. Public Health England. The treatment and prophylaxis of influenza: 2014-15, November 2014. Available from:

https://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents

http://bit.ly/1BrnRuwhttp://www.ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=%7b4F55AD51-4AED-4D32-B960-AF70113DBB90%7d&ID=1234http://www.ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=%7b4F55AD51-4AED-4D32-B960-AF70113DBB90%7d&ID=1234http://emergency.cdc.gov/han/han00374.asphttp://www.cdc.gov/flu/professionals/antivirals/antiviral-use-influenza.htm#chemoprophylaxishttp://guidance.nice.org.uk/TA168http://www.who.int/csr/resources/publications/swineflu/h1n1_use_antivirals_20090820/enhttps://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents

210-5212000, 210-5212054 www.keelpno.gr

9